Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Design Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 96
- +13 vs. Q4 2022
- Shares held
- 38.7M
- −1.68M (−4.2%) vs. Q4 2022
- Total value
- $223.3M
- −$190.9M (−46.1%) vs. Q4 2022
- New holders
- 32
- 23 more added
- Sold out
- 19
- 27 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DSGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 136 | $626.4M |
| Q1 2026 | 125 | $404.1M |
| Q4 2025 | 117 | $357.6M |
| Q3 2025 | 95 | $259.7M |
| Q2 2025 | 93 | $116.4M |
| Q1 2025 | 98 | $133.0M |
| Q4 2024 | 95 | $206.5M |
| Q3 2024 | 100 | $172.3M |
| Q2 2024 | 95 | $107.5M |
| Q1 2024 | 93 | $123.9M |
| Q4 2023 | 88 | $84.0M |
| Q3 2023 | 87 | $77.6M |
| Q2 2023 | 97 | $244.4M |
| Q1 2023 | 96 | $223.3M |
| Q4 2022 | 83 | $414.2M |
| Q3 2022 | 79 | $667.2M |
| Q2 2022 | 74 | $541.7M |
| Q1 2022 | 63 | $613.7M |
| Q4 2021 | 60 | $773.1M |
| Q3 2021 | 52 | $414.8M |
| Q2 2021 | 50 | $546.2M |
| Q1 2021 | 43 | $755.2M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Design Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −57,025−100.0% | Sold out |
| Bellevue Group AG | 0 | $0 | 0.00% | −34,881−100.0% | Sold out |
| Virtus Investment Advisers, Inc. | 0 | $0 | 0.00% | −14,400−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −12,523−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −12,236−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −11,568−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −10,703−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −1,669−100.0% | Sold out |
| High Net Worth Advisory Group LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −201−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −84−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −61−100.0% | Sold out |